learn GT20029
research compound made to degrade androgen receptors in scalp
Search
forLearn
2 / 2 resultslearn KY19382
compound that activates Wnt/β-catenin to promote hair regrowth and create new hair follicles
Research
4 / 4 results
research Topical Solutions for Androgenetic Alopecia: Evaluating Efficacy and Safety
Topical treatments for hair loss can be effective but need careful safety evaluation.
research What's New in Therapy for Male Androgenetic Alopecia?
research Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Adding a second method to PROTACs could improve cancer treatment.
research Androgens and Androgen Receptor in the Management of Skin Diseases
Understanding how androgens and their receptors work can lead to improved treatments for skin diseases.
Community Join
5 / 236 resultscommunity How much will GT20029 cost if it becomes FDA approved?
The conversation is about the potential cost of GT20029 if FDA approved, with estimates around $150/month. Comparisons are made between GT20029, finasteride, and their mechanisms and side effects.
community Q1 2024 is done. And kintor is completely silent about GT20029.
The conversation discusses the lack of updates on GT20029 for hair loss treatment, with some users noting recent reports indicating ongoing data collection. There are mentions of other treatments like Pyrilutamide and Minoxidil.
community Comprehensive list of Hair loss treatments and your opinion on the best combination to us.
The conversation discusses using oral Minoxidil, topical Minoxidil with RU58841, Finasteride, and serioxyl for hair loss. It also asks for opinions on the effectiveness of other treatments like Setipiprant, Dutasteride, and Spironolactone, and thoughts on HMI-115 and GT20029 trials.
community The Cure isn't 5 years away; it's already here.
PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.
community HMI-115: What We Know So Far. HMI-115 (also known as BAY1158061) is a new pharmaceutical drug developed by a biopharmaceutical company called Bioinvent and licensed by Bayer
HMI-115 is a new drug developed by Bioinvent and licensed by Bayer, with mixed opinions on its potential effectiveness. Some users are skeptical and prefer proven treatments like Minoxidil, finasteride, and RU58841.